welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
UT Researcher, With CureDuchenne Support, Launches Company to Treat DMD Using CRISPR/Cas9 Technology
Eric Olson, a molecular biologist, has spent more than half his life in the lab. Now, the 62-year-old University of Texas researcher and distinguished professor is a businessman as well.
Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.
The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD).
rareRelated
-
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a f...
-
Dr. Eric Olson CRISPR/Cas9 Presentation at CureDuchenne Careshttps://www.youtube.com/watch?v=P-Q8HFXk...
-
The Gene-Edited Babies And CRISPR-Cas9 Controversy, ExplainedOutrage continues to grow over the news ...
-
Crispr Halted Muscular Dystrophy In Dogs. Someday, It Might Cure Humans.Today, our partner Dr. Eric Olson and hi...
-
CRISPR/Cas9-Generated Mouse Model of Duchenne Muscular Dystrophy Recapitulating a Newly Identified Large 430 Kb Dele...Exon skipping is a promising strategy fo...
-
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exon...CureDuchenne, a nonprofit global leader ...
-
New CRISPR technique skips over portions of genes that can cause diseaseIn a new study in cells, researchers hav...
